SUCCESSFUL MANAGEMENT OF LOW-STAGE NEUROBLASTOMA WITHOUT ADJUVANT THERAPIES - A COMPARISON OF 2 DECADES, 1972 THROUGH 1981 AND 1982 THROUGH1992, IN A SINGLE INSTITUTION

Citation
Ae. Evans et al., SUCCESSFUL MANAGEMENT OF LOW-STAGE NEUROBLASTOMA WITHOUT ADJUVANT THERAPIES - A COMPARISON OF 2 DECADES, 1972 THROUGH 1981 AND 1982 THROUGH1992, IN A SINGLE INSTITUTION, Journal of clinical oncology, 14(9), 1996, pp. 2504-2510
Citations number
23
Categorie Soggetti
Oncology
ISSN journal
0732183X
Volume
14
Issue
9
Year of publication
1996
Pages
2504 - 2510
Database
ISI
SICI code
0732-183X(1996)14:9<2504:SMOLNW>2.0.ZU;2-#
Abstract
Purpose: A review was undertaken of 119 children seen at the Children' s Hospital of Philadelphia between 1972 and 1992 to assess the impact of adjuvant therapies for patients with low-stage neuroblastoma (NBL). Patients and Methods: Twenty-one of 119 International Neuroblastoma S taging System (INSS) stage 1, 2a, 2b, and 4s patients seen received in itial adjuvant treatment postoperatively and 98 did not. The patients were further subdivided according to decade, age, presence of residual disease, and lymph node status. Outcomes were then compared. Results: The event-free survival (EFS) rate for those who received adjuvant th erapy was 52% versus 86% for those who did not. The 5-year survival ra te was 68% and 94%, respectively. Age (< or > 12 months), extent of re sidual disease, and status of lymph nodes did not influence survival, Over the two decades, the reasons for selecting treatment changed as n ew and powerful additional prognostic factors were identified; 71% of patients received no adjuvant treatment in the first decade, compared with 90% in the second, EFS rates for untreated patients by decade wer e 79% and 89%, and 5-year survival rates were 85% and 98%, respectivel y. Conclusion: It is possible to define most low-stage NBL as favorabl e-even in patients with positive lymph nodes and gross residual diseas e-and to omit initial adjuvant treatments successfully. (C) 1996 by Am erican Society of Clinical Oncology.